Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1851 Harbor Bay Parkway ALAMEDA CA 94502 |
Tel: | N/A |
Website: | https://www.exelixis.com |
IR: | See website |
Key People | ||
Michael M. Morrissey President, Chief Executive Officer, Director | Christopher J. Senner Chief Financial Officer, Executive Vice President | Dana T. Aftab Executive Vice President - Discovery and Translational Research, Chief Scientific Officer |
Jeffrey J. Hessekiel Executive Vice President, General Counsel, Secretary | Patrick Joseph Haley Executive Vice President - Commercial | Amy Peterson Executive Vice President, Product Development & Medical Affairs and Chief Medical Officer | Peterson C. Peterson Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer |
Business Overview |
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension. |
Financial Overview |
For the fiscal year ended 29 December 2023, Exelixis Inc revenues increased 14% to $1.83B. Net income increased 14% to $207.8M. Revenues reflect CABOMETYX segment increase of 17% to $1.61B, License revenues segment increase of 10% to $178.6M, U.S segment increase of 16% to $1.65B, Japan segment increase of 37% to $39.5M. Net income also reflects Interest Income increase from $33.1M to $86.5M (income). |
Employees: | 1,310 as of Dec 29, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $5,824M as of Dec 29, 2023 |
Annual revenue (TTM): | $1,830M as of Dec 29, 2023 |
EBITDA (TTM): | $196.60M as of Dec 29, 2023 |
Net annual income (TTM): | $207.77M as of Dec 29, 2023 |
Free cash flow (TTM): | $292.86M as of Dec 29, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 303,194,259 as of Jan 29, 2024 |
Index Membership: | S&P 400 Mid Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |